Loading...
•
Dec 31, 2022
Integra LifeSciences Q4 2022 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2022.
Key Takeaways
Integra LifeSciences reported Q4 2022 revenues of $398.0 million, a decrease of 1.8% compared to Q4 2021, but an increase of 2.9% on an organic basis. GAAP earnings per diluted share were $0.63, and adjusted earnings per diluted share were $0.94.
Reported revenues were $398.0 million, a decrease of 1.8% on a reported basis and an increase of 2.9% on an organic basis compared to Q4 2021.
GAAP earnings per diluted share were $0.63, compared to $0.53 in Q4 2021.
Adjusted earnings per diluted share were $0.94, compared to $0.84 in Q4 2021.
GAAP net income was $52.9 million, compared to $45.4 million in the prior year.
Forward Guidance
For the full-year 2023, the Company expects revenues to be in a range of $1,602 million to $1,620 million, representing reported growth of approximately 2.9% to 4.0% and organic growth in the range of 4.0% to 5.2%. Adjusted earnings per diluted share are expected to be between $3.43 and $3.51.
Positive Outlook
- Recovery of markets back to pre-COVID levels
- Gradual improvement in supply over the year
- Relaunch of CereLink in the first half
- Impact of commercial capability build-out and new products
- Recent acquisition of DuraSorb
Challenges Ahead
- Divestiture of the TWC business.
- Guidance reflects a sequential improvement from first to second half growth primarily driven by the gradual recovery of supply throughout the year
- 2022 normalization from our private label business
- The recovery of our China business post-COVID lockdowns
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...